# iRhythm Holdings, Inc.: overview

IRTC · Nasdaq · CIK 1388658 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/irtc.md) · [Financials](/companies/irtc/financials.md) · [Filings](/companies/irtc/filings.md) · [Insiders](/companies/irtc/insiders.md)

Latest reported revenue: [$224.2m](/filings/0001388658-26-000072.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001388658-26-000072).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [148](/filings/0001388658-25-000217.md) | [164 d](/filings/0001388658-26-000011.md) | [159](/filings/0001388658-26-000039.md) | [187](/filings/0001388658-26-000072.md) | [193](/filings/0001388658-25-000217.md) | [209 d](/filings/0001388658-26-000011.md) | [199](/filings/0001388658-26-000039.md) | [224](/filings/0001388658-26-000072.md) |
| Gross margin | % | [68.8%](/filings/0001388658-25-000217.md) | [70.0% d](/filings/0001388658-26-000011.md) | [68.8%](/filings/0001388658-26-000039.md) | [71.2%](/filings/0001388658-26-000072.md) | [71.1%](/filings/0001388658-25-000217.md) | [70.9% d](/filings/0001388658-26-000011.md) | [70.9%](/filings/0001388658-26-000039.md) | [72.8%](/filings/0001388658-26-000072.md) |
| Operating margin | % | [(34.1%)](/filings/0001388658-25-000217.md) | [(2.5%) d](/filings/0001388658-26-000011.md) | [(20.5%)](/filings/0001388658-26-000039.md) | [(10.0%)](/filings/0001388658-26-000072.md) | [(4.4%)](/filings/0001388658-25-000217.md) | [1.1% d](/filings/0001388658-26-000011.md) | [(8.1%)](/filings/0001388658-26-000039.md) | [(1.1%)](/filings/0001388658-26-000072.md) |
| Net margin | % | [(31.3%)](/filings/0001388658-25-000217.md) | [(0.8%) d](/filings/0001388658-26-000011.md) | [(19.3%)](/filings/0001388658-26-000072.md) | [(7.6%)](/filings/0001388658-26-000072.md) | [(2.7%)](/filings/0001388658-25-000217.md) | [2.7% d](/filings/0001388658-26-000011.md) | [(7.0%)](/filings/0001388658-26-000072.md) | [(0.2%)](/filings/0001388658-26-000072.md) |
| Diluted EPS | $ per share | [(1.48)](/filings/0001388658-25-000217.md) | not reported | [(0.97)](/filings/0001388658-26-000039.md) | [(0.44)](/filings/0001388658-26-000072.md) | [(0.16)](/filings/0001388658-25-000217.md) | not reported | [(0.43)](/filings/0001388658-26-000039.md) | [(0.01)](/filings/0001388658-26-000072.md) |
| Free cash flow | $m | [15.5 d](/filings/0001388658-25-000217.md) | [12.4 d](/filings/0001388658-26-000011.md) | [(17.3)](/filings/0001388658-26-000039.md) | [17.3 d](/filings/0001388658-26-000072.md) | [20.1 d](/filings/0001388658-25-000217.md) | [14.5 d](/filings/0001388658-26-000011.md) | [(33.1)](/filings/0001388658-26-000039.md) | [37.5 d](/filings/0001388658-26-000072.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [323](/filings/0001388658-24-000014.md) | [411](/filings/0001388658-25-000028.md) | [493](/filings/0001388658-26-000011.md) | [592](/filings/0001388658-26-000011.md) | [747](/filings/0001388658-26-000011.md) |
| Gross margin | % | [66.2%](/filings/0001388658-24-000014.md) | [68.5%](/filings/0001388658-25-000028.md) | [67.3%](/filings/0001388658-26-000011.md) | [68.9%](/filings/0001388658-26-000011.md) | [70.6%](/filings/0001388658-26-000011.md) |
| Operating margin | % | [(31.0%)](/filings/0001388658-24-000014.md) | [(27.7%)](/filings/0001388658-25-000028.md) | [(25.4%)](/filings/0001388658-26-000011.md) | [(19.5%)](/filings/0001388658-26-000011.md) | [(7.7%)](/filings/0001388658-26-000011.md) |
| Net margin | % | [(31.4%)](/filings/0001388658-24-000014.md) | [(28.3%)](/filings/0001388658-25-000028.md) | [(25.0%)](/filings/0001388658-26-000011.md) | [(19.1%)](/filings/0001388658-26-000011.md) | [(6.0%)](/filings/0001388658-26-000011.md) |
| Diluted EPS | $ per share | [(3.46)](/filings/0001388658-24-000014.md) | [(3.88)](/filings/0001388658-25-000028.md) | [(4.04)](/filings/0001388658-26-000011.md) | [(3.63)](/filings/0001388658-26-000011.md) | [(1.39)](/filings/0001388658-26-000011.md) |
| Free cash flow | $m | [(65.8)](/filings/0001388658-24-000014.md) | [(52.8)](/filings/0001388658-25-000028.md) | [(90.5)](/filings/0001388658-26-000011.md) | [(30.6)](/filings/0001388658-26-000011.md) | [34.5](/filings/0001388658-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/irtc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $355.1m | 2,985,667 |  | Added +244,162 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $259.6m | 2,182,631 |  | Added +514,131 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $227.7m | 1,913,976 |  | Added +117,604 |
| [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $197.5m | 1,660,307 |  | Added +209,400 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $174.0m | 1,463,211 |  | Added +17,501 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $167.3m | 1,406,454 |  | Reduced −201,560 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $141.8m | 1,191,982 |  | Reduced −169,937 |
| [UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC](/funds/861177.md) | 2026-06-30 | $112.4m | 944,517 |  | Reduced −102,935 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $104.9m | 881,899 |  | Added +64,789 |
| [EVENTIDE ASSET MANAGEMENT, LLC](/funds/1442891.md) | 2026-06-30 | $104.7m | 880,338 |  | Added +119,513 |

## Recent filings

[All 845 filings](/companies/irtc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 13:07 ET | [8-K](/filings/0001388658-26-000083.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001388658-26-000083 |
| 2026-09-22 | 21:00 ET | [8-K](/filings/0001388658-26-000080.md) | 7.01 Regulation FD disclosure | 0001388658-26-000080 |
| 2026-08-13 | 20:15 ET | [8-K](/filings/0001388658-26-000076.md) | 5.02 Departure or appointment of officers or directors | 0001388658-26-000076 |
| 2026-08-06 | 21:21 ET | [10-Q](/filings/0001388658-26-000072.md) | Quarterly report, period 2026-06-30 | 0001388658-26-000072 |
| 2026-08-06 | 21:15 ET | [8-K](/filings/0001388658-26-000071.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001388658-26-000071 |
| 2026-08-06 | 20:15 ET | [8-K](/filings/0001388658-26-000070.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001388658-26-000070 |
| 2026-06-15 | 20:30 ET | [8-K](/filings/0001388658-26-000055.md) | 1.05 Material cybersecurity incident | 0001388658-26-000055 |
| 2026-06-05 | 11:47 ET | [8-K](/filings/0001388658-26-000052.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001388658-26-000052 |
| 2026-05-28 | 11:33 ET | [8-K](/filings/0001388658-26-000049.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001388658-26-000049 |
| 2026-04-30 | 21:21 ET | [10-Q](/filings/0001388658-26-000039.md) | Quarterly report, period 2026-03-31 | 0001388658-26-000039 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001388658-26-000011.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9acd1921-8268-48bb-90ac-a03986de1476)

## About the filer

- CIK: 1388658
- Tickers: IRTC
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.